Jiang Jianing, Gao Jinqi, Ben Jing, Wang Gang, Duan Wenqi, Liu Hao, Jin Qianchen, Wang Ruoyu, Lv Jinyan
Department of Oncology Medicine, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Liaoning Province, China.
J Int Med Res. 2024 Dec;52(12):3000605241305429. doi: 10.1177/03000605241305429.
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with the poorest prognosis among all types of lung cancer. Developing an effective comprehensive strategy remains a key focus. We herein present the first documented case of a 68-year-old man with limited-stage SCLC who has maintained a complete response (CR) for over 30 months to date. CR was achieved with first-line chemotherapy using etoposide and carboplatin combined with chest volumetric-modulated arc therapy. Maintenance therapy with anlotinib extended the progression-free survival to 20 months after first-line therapy. When resistance developed, second-line therapy with albumin-bound paclitaxel, carboplatin, and the immune checkpoint inhibitor durvalumab sustained CR for 7 months. Third-line therapy with etoposide and cisplatin combined with durvalumab has maintained CR to date.
小细胞肺癌（SCLC）是一种侵袭性神经内分泌肿瘤，在所有类型的肺癌中预后最差。制定有效的综合策略仍然是关键重点。我们在此报告首例有记录的68岁局限性小细胞肺癌男性患者，迄今为止已维持完全缓解（CR）超过30个月。通过使用依托泊苷和卡铂联合胸部容积调强弧形放疗的一线化疗实现了CR。使用安罗替尼的维持治疗将一线治疗后的无进展生存期延长至20个月。当出现耐药时，使用白蛋白结合型紫杉醇、卡铂和免疫检查点抑制剂度伐利尤单抗的二线治疗使CR持续了7个月。使用依托泊苷和顺铂联合度伐利尤单抗的三线治疗迄今为止维持了CR。
